Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions.
Chromothripsis
Copy- number variation
Multiple myeloma
Mutational signature
Journal
Seminars in oncology
ISSN: 1532-8708
Titre abrégé: Semin Oncol
Pays: United States
ID NLM: 0420432
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
15
10
2021
accepted:
08
01
2022
pubmed:
17
2
2022
medline:
1
6
2022
entrez:
16
2
2022
Statut:
ppublish
Résumé
All patients with a diagnosis of multiple myeloma (MM) have a preceding, asymptomatic expansion of clonal plasma cells, clinically recognized as monoclonal gammopathy of undetermined significance or smoldering multiple myeloma (SMM). While most patients with monoclonal gammopathy of undetermined significance have a very small rate of progression, SMM is a widely heterogeneous condition where a fraction of patients will progress to symptomatic MM rather quickly, while others will experience an indolent clinical course. The differentiation between progressive and stable precursor condition thus represents one of the most important unmet clinical needs in the MM community. The ability to identify patients at high-risk of progression before major clonal expansion and onset of end-organ damage would enable strategies for early prevention and perhaps more effective intervention. All proposed criteria to predict the progression of myeloma precursor conditions are built around indirect markers of disease burden and, therefore, are generally able to accurately identify only a small fraction of patients in whom progression to MM is already occurring. Leveraging whole genome and exome sequencing, it has been shown that patients with stable myeloma precursor conditions are characterized by either absence or lower prevalence of distinct genomic events that are detectable in progressive precursor condition years before the progression. In this review, we discuss evolving genomic concepts and tools; and their ability to differentiate myeloma precursor conditions into two distinct entities: one benign (monoclonal gammopathy of benign significance) and another malignant (asymptomatic multiple myeloma).
Identifiants
pubmed: 35168813
pii: S0093-7754(22)00006-9
doi: 10.1053/j.seminoncol.2022.01.006
pmc: PMC9149131
mid: NIHMS1772447
pii:
doi:
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-18Subventions
Organisme : NCI NIH HHS
ID : P30 CA240139
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
Nature. 2020 Feb;578(7793):112-121
pubmed: 32025012
N Engl J Med. 2018 Jan 18;378(3):241-249
pubmed: 29342381
JAMA Oncol. 2021 Jan 1;7(1):132-134
pubmed: 33211080
Nat Commun. 2021 Mar 25;12(1):1861
pubmed: 33767199
Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):248-57
pubmed: 20709660
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Leukemia. 2022 Feb;36(2):591-595
pubmed: 34365473
Cancer Cell. 2014 Jan 13;25(1):91-101
pubmed: 24434212
Nat Rev Cancer. 2012 Apr 12;12(5):335-48
pubmed: 22495321
JAMA Oncol. 2020 Mar 1;6(3):425-432
pubmed: 31830214
Genome Res. 2018 May;28(5):654-665
pubmed: 29632087
J Clin Oncol. 2020 Jul 20;38(21):2380-2389
pubmed: 32442065
Clin Cancer Res. 2021 Jan 1;27(1):15-23
pubmed: 32759358
N Engl J Med. 1980 Jun 12;302(24):1347-9
pubmed: 7374679
N Engl J Med. 2007 Jun 21;356(25):2582-90
pubmed: 17582068
Acta Med Scand. 1984;216(5):435-47
pubmed: 6441456
Haematologica. 2017 Sep;102(9):1617-1625
pubmed: 28550183
Nature. 2019 Oct;574(7779):532-537
pubmed: 31645730
Blood. 2018 Aug 9;132(6):587-597
pubmed: 29884741
Nat Commun. 2020 Apr 21;11(1):1917
pubmed: 32317634
Leukemia. 2019 Jan;33(1):159-170
pubmed: 29967379
Nat Genet. 2017 Mar;49(3):341-348
pubmed: 28112740
Am J Hematol. 2016 Jul;91(7):719-34
pubmed: 27291302
Nat Commun. 2019 Jul 5;10(1):2969
pubmed: 31278357
Nat Commun. 2021 Jan 12;12(1):293
pubmed: 33436579
Nat Commun. 2020 Jul 17;11(1):3617
pubmed: 32680998
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Leukemia. 2020 Jan;34(1):322-326
pubmed: 31439946
Nat Commun. 2019 Aug 23;10(1):3835
pubmed: 31444325
Nat Commun. 2015 Apr 23;6:6997
pubmed: 25904160
Cancer Discov. 2015 Jul;5(7):704-12
pubmed: 26091828
Leukemia. 2021 May;35(5):1511-1515
pubmed: 33483619
Clin Cancer Res. 2017 Jun 1;23(11):2617-2629
pubmed: 28572256
Nat Commun. 2014;5:2997
pubmed: 24429703
Leukemia. 2014 Feb;28(2):384-390
pubmed: 23817176
Leukemia. 2021 Aug;35(8):2145-2150
pubmed: 34012133
Int J Hematol. 2013 Mar;97(3):313-23
pubmed: 23456262
Leukemia. 2018 Apr;32(4):1044-1048
pubmed: 29209044
Am J Med. 1978 May;64(5):814-26
pubmed: 645746
Nat Commun. 2018 Aug 22;9(1):3363
pubmed: 30135448
Blood Cancer J. 2018 Jun 12;8(6):59
pubmed: 29895887
Nat Genet. 2019 Dec;51(12):1732-1740
pubmed: 31740835
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Leukemia. 2010 Jun;24(6):1121-7
pubmed: 20410922
Clin Cancer Res. 2007 Oct 15;13(20):6026-31
pubmed: 17947464
Blood. 2016 Sep 29;128(13):1735-44
pubmed: 27516441
Blood Cancer Discov. 2020 Nov;1(3):258-273
pubmed: 33392515